吉非替尼联合用药对肺癌敏感A549、耐药A549/GR细胞株的实验研究  

Experimental study on gefitinib combination in treatment of sensitive lung cancer A549,resistant A549/GR cell lines

作　　者：李娟[1] 李宝平[1] 张雷[1] 梁娟[1] 

机构地区：[1]山西医科大学第二医院肿瘤生物治疗科,山西太原030001

出　　处：《中国现代医生》2014年第14期24-27,共4页China Modern Doctor

摘　　要：目的研究吉非替尼联合用药对肺癌敏感A549、耐药A549/GR细胞株的影响。方法用四甲基偶氮唑蓝(MTT)法检测和培养肺癌敏感A549和耐药A549/GR细胞株,待24 h、48 h、72 h后采用不同浓度的吉非替尼、奥曲肽、顺铂、5-FU进行单用和联用处理,流式细胞术检测细胞凋亡率,分析药物的增效效果。结果联合用药对肺癌敏感A549和耐药A549/GR细胞株可起到协同抑制作用,与单独用药组比较,差异有统计学意义(P<0.05)。联合用药组的肺癌敏感A549、耐药A549/GR细胞株培育48 h后的IC50=(5.3±0.5)、(5.4±0.8)mg/L,单药组IC50=(20.1±1.2)、(20.3±1.4)mg/L,差异有统计学意义(P<0.05)。对照组、单药组、联合用药组诱导肺癌敏感A549和耐药A549/GR细胞株后凋亡率差异明显,差异有统计学意义(P<0.05)。结论吉非替尼联合用药对细胞的增生具有协同抑制作用,对其他肺癌的治疗也具有一定的效果。Objective To examinat the influence of gefitinib combination for sensitive lung cancer A549 and resistant A549/GR cell lines. Methods The sensitive lung cancer A549 and resistant A549/GR cell lines were detected and cultured by Tetrazolium blue（MTT）,then received different concentrations of gefitinib,octreotide,cisplatin,5-FU alone and in combination with processing after 24 h,48 h,72 h,the apoptosis rate was detected by flow cytometry,and the synergistic effects of drugs were analysised. Results The combination of sensitive A549 lung cancer and A549/GR resistant cell lines played a synergistic inhibitory effect,compared with alone group,the difference was statistical significance （P〈0.05）; Tured after 48h, the sensitive lung cancer A549 and resistant A549/GR cell lines in combined groupcul were IC50=（5.3±0.5）,（5.4±0.8） mg/L,the single drug group IC50=（20.1±1.2）,（20.3±1.4） mg/L,the difference was statistical significance （P〈0.05）; After the induction of lung cancer A549 and sensitive cell lines and drug A549/GR,the apoptosis rate of control group,monotherapy group,the combined group were statistical significance （P〈0.05）. Conclusion Gefitinib combination has a synergistic inhibitory effect on cell proliferation,and also has a certain effect on other cancer therapy.

关 键 词：吉非替尼 奥曲肽 肺癌敏感A549 顺铂 Sensitive LUNG cancer A549 

分 类 号：R734.2[医药卫生—肿瘤]